International Journal of Biomedical Engineering and Clinical Science

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Predicative Meaning of Radioiodine Pharmacokinetics Indices for Evaluation of Radioablation Efficacy of Thyroid Residuum in Patients with Differentiated Thyroid Cancer

Background: The radioiodine ablation (RIA) of thyroid residuum in patients with differentiated thyroid cancer (DTC) is an important stage of complex treatment. The aim of RIA is the elimination of potential foci of DTC and creating conditions for monitoring of the patients. Prognosis of the efficacy of RIA is important for further planning of the complex treatment. The aim of the study was to improve a prognosis of RIA of thyroid residual tissue (TRT) in patients with DTC using scintigraphic date about 131I kinetics, that reflect a radioresistance of a thyroid tissue. Material and Methods: The results of RIA of TRT in 62 patients were analyzed. During radioiodine therapy (RIT) the elimination halftime of 131I from TRT in time interval 3–6 days after administration of therapeutic activities was determined, and the focal radiation adsorbed doses (FRAD) in TRT were calculated. Results: It was determined that values Т1/2 ≥ 4.0 days may indicate on the high probability of the incomplete RIA of TRT at FRAD within 50–500 Gy, while values Т1/2 ≤ 1.9 days – on the radiosensitivity of the thyroid tissue and the great probability of the complete RIA. Conclusions: During RIT of DCT the elimination halftime of iodine-131, determined on time interval 3–6 days after the administration of therapeutic activities may be used as one of predicative indices of RIA efficacy. Since the elimination halftime of the radiopharmaceutical reflects the individual natural radiosensitivity of TRT, this approach may be applied in studies of the radioresistance of a normal human tissue.

Differentiated Thyroid Cancer, Radioiodine Therapy, Radioiodine Ablation, Residual Thyroid Tissue, Prognosis of Radioiodine Ablation Efficacy

APA Style

Dmitry Dzhuzha. (2023). Predicative Meaning of Radioiodine Pharmacokinetics Indices for Evaluation of Radioablation Efficacy of Thyroid Residuum in Patients with Differentiated Thyroid Cancer. International Journal of Biomedical Engineering and Clinical Science, 9(3), 56-59. https://doi.org/10.11648/j.ijbecs.20230903.14

ACS Style

Dmitry Dzhuzha. Predicative Meaning of Radioiodine Pharmacokinetics Indices for Evaluation of Radioablation Efficacy of Thyroid Residuum in Patients with Differentiated Thyroid Cancer. Int. J. Biomed. Eng. Clin. Sci. 2023, 9(3), 56-59. doi: 10.11648/j.ijbecs.20230903.14

AMA Style

Dmitry Dzhuzha. Predicative Meaning of Radioiodine Pharmacokinetics Indices for Evaluation of Radioablation Efficacy of Thyroid Residuum in Patients with Differentiated Thyroid Cancer. Int J Biomed Eng Clin Sci. 2023;9(3):56-59. doi: 10.11648/j.ijbecs.20230903.14

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Haugen BR, Alexander EK, Bile KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26 (1): 1–133. doi.org/10.1089/thy.2015.0020.
2. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Franco FS, Smit J, Wiersinga W (2005) Post-surgical use radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 153 (5): 651–659. doi.org/10.1530/eje.1.02014.
3. Stewart LA, Kuo JH (2021) Advancements in the treatment of differential thyroid cancer. Ther Adv Endocrinol Metab 12: 1–13. doi. org/ 10.1177/20420188211000251.
4. Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold R, Papotti VG, Berruti A; ESMO Guidelines Committee (2019) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30 (12): 1856–1883. doi. org/10.1093/annonc/mdz400.
5. Hackshaw A, Yarmer C, Mallick U, Haq M, Franklyn JA (2006) 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Methab 92 (1): 28–38. doi. org/10.1210/jc.2006-1345.
6. Bal CS, Padhy AK (2015) Radioiodine remnant ablation: a critical review. World J Nucl Med 14 (3): 144–155. doi. org/10.4103/1450-1147.163240.
7. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Brownman G, Gerstein HC (2004) A systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89 (8): 3668–3676. doi. org/10.1210/jc.2003-031167.
8. Haugen BR (2004) Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. J Clin Endocrinol Metab 89 (8): 3665–3667. doi. org/10.1210/jc.2004-0920.
9. Robbins RJ, Schlumberger MJ (2005) The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46 (Suppl 1): 28S–37S.
10. Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K, Harmer CL (2010) A dose- effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 37 (2): 270–275. doi. org/10.1007/S00259-009-1261-3.
11. Wierts R, Brans B, Havekes B, Kemerink GJ, Halders SG, Schaper NN, Backes WH, Mottaghy FM, Jentzen W (2016) Dose-response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET/CT. J Nucl Med 57: 1027–1032. doi. org/10.2967/jnumed.115.168799.
12. Maxon HR 3 rd (1993) The role of 131I in the treatment of thyroid cancer. Thyroid today 26 (2): 1–9.
13. Maxon HR 3 rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld Ш, Chen LS, Smith H, Cumraings D, Aden MD (1992) Radioiodine-I31 Therapy for well-differentiated thyroid cancer: a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 33 (6): 1132–1136.
14. Bal C, Padhy AK, Jana S, Pant GS, Basu AK (1996) Prospective randomized clinical trial to evaluate the optimal dose of 131-I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77 (12): 2574–2580. doi org/10/1002/(SICI)1097-0142(19960615)77: 12<2574:: AIR-CNCR22>3.0. CO; 2-0.
15. Brown P. H. Mathematics and statistics. Nuclear medicine technology and techniques. St. Louis: Mosby; 1997: 1–35.
16. Tautz M (1976) Dose calculation for thyroid radiation therapy according to MIRD recommendations [Dosisberechnung bei der Strahlentherapie der Schilddruse nash den MIRD-Empfehlungen]. Radiobiol Radiother (Berl) 17 (1): 71–75. German.
17. Loevnger R, Budinger TF, Watson EE. MIRD primer for adsorbed dose calculation. New York: The Society of Nuclear Medicine; 1988: 193 p.